BDBM551674 (2S,3S or 2R,3R)-3-(4-((3R,5S or 3S,5R)-3-(5-amino-9- fluoro-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-2-yl)-5- methylpiperidin-1-yl)-5-methyl-1H-pyrazol-1-yl)butan-2-ol::US11312719, Example 220::US11312719, Example 221::US11312719, Example 222::US11312719, Example 223

SMILES COc1cc(F)cc2c3nc(nn3c(N)nc12)C1CC(C)CN(C1)c1cnn(C(C)C(C)O)c1C

InChI Key InChIKey=CVSBSUJPNTUQJR-UHFFFAOYSA-N

Data  7 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 7 hits for monomerid = 551674   

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM551674(US11312719, Example 223 | (2S,3S or 2R,3R)-3-(4-((...)
Affinity DataIC50: 0.5nMAssay Description:The ability of compounds to antagonize human A2A and A2B adenosine receptors was determined using a kit to measure changes in intracellular cyclic AM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM551674(US11312719, Example 223 | (2S,3S or 2R,3R)-3-(4-((...)
Affinity DataIC50: 0.700nMAssay Description:The ability of compounds to antagonize human A2A and A2B adenosine receptors was determined using a kit to measure changes in intracellular cyclic AM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM551674(US11312719, Example 223 | (2S,3S or 2R,3R)-3-(4-((...)
Affinity DataIC50: 20.4nMAssay Description:The ability of compounds to antagonize human A2A and A2B adenosine receptors was determined using a kit to measure changes in intracellular cyclic AM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetAdenosine receptor A2a(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM551674(US11312719, Example 223 | (2S,3S or 2R,3R)-3-(4-((...)
Affinity DataIC50: 34.6nMAssay Description:The ability of compounds to antagonize human A2A and A2B adenosine receptors was determined using a kit to measure changes in intracellular cyclic AM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetAdenosine receptor A2b(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM551674(US11312719, Example 223 | (2S,3S or 2R,3R)-3-(4-((...)
Affinity DataIC50: 46nMAssay Description:The ability of compounds to antagonize human A2A and A2B adenosine receptors was determined using a kit to measure changes in intracellular cyclic AM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetAdenosine receptor A2b(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM551674(US11312719, Example 223 | (2S,3S or 2R,3R)-3-(4-((...)
Affinity DataIC50: 63nMAssay Description:The ability of compounds to antagonize human A2A and A2B adenosine receptors was determined using a kit to measure changes in intracellular cyclic AM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent

TargetAdenosine receptor A2b(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM551674(US11312719, Example 223 | (2S,3S or 2R,3R)-3-(4-((...)
Affinity DataIC50: 3.28E+3nMAssay Description:The ability of compounds to antagonize human A2A and A2B adenosine receptors was determined using a kit to measure changes in intracellular cyclic AM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2022
Entry Details
US Patent